Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | 35.24 |
2 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | 12.74 |
3 | Treatment of metastatic melanoma: an overview. | Oncology (Williston Park) | 2009 | 4.58 |
4 | An antigen produced by splicing of noncontiguous peptides in the reverse order. | Science | 2006 | 2.18 |
5 | Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. | Oncotarget | 2013 | 1.44 |
6 | Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. | Blood | 2013 | 1.17 |
7 | HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. | J Immunol | 2013 | 0.92 |
8 | Systemic therapy of metastatic melanoma: on the road to cure. | Oncology (Williston Park) | 2015 | 0.81 |